Boston Scientific took two separate rating cuts in quick succession. Oppenheimer lowered its stance on the medical device maker citing growth concerns, while TD Cowen cut its rating over worries specific to the company's 2027 outlook.
When two brokers downgrade the same stock on the same day but cite different time horizons, it usually means the concern is not a single data point but a pattern analysts expect to persist. Oppenheimer's focus on near-term growth and TD Cowen's focus on 2027 together suggest the doubts are not confined to one upcoming quarter.
Neither note detailed a specific earnings miss or guidance cut from the company itself in the material available; the downgrades appear to be analyst-driven calls on where growth is headed rather than a reaction to a company disclosure. That leaves open whether Boston Scientific's own forward guidance, when it next updates the market, will confirm or push back on the brokers' view.
What is unresolved is which specific product lines or markets are behind the growth concern — the available notes name the rating change but not the underlying driver in detail.